DOI QR코드

DOI QR Code

Increased Free Circulating DNA Integrity Index as a Serum Biomarker in Patients with Colorectal Carcinoma

  • El-Gayar, Dina (Clinical and Chemical Pathology, Faculty of Medicine, Cairo University) ;
  • El-Abd, Nevine (Clinical and Chemical Pathology, Faculty of Medicine, Cairo University) ;
  • Hassan, Noha (Clinical and Chemical Pathology, National Cancer Institute, Cairo University) ;
  • Ali, Reem (Clinical and Chemical Pathology, National Cancer Institute, Cairo University)
  • Published : 2016.04.11

Abstract

Background: Cell-free DNA circulating in blood is a candidate biomarker for malignant tumors. Unlike uniformly truncated DNA released from apoptotic non diseased cells, DNA released from necrotic cancer cells varies in size. Objectives: To measure the DNA integrity index in serum and the absolute DNA concentration to assess their clinical utility as potential serum biomarkers for colorectal carcinoma (CRC) compared to CEA and CA19-9. Materials and Methods: Fifty patients with CRC, 10 with benign colonic polyps and 20 healthy sex and age matched volunteers, were investigated by real time PCR of ALU repeats (ALU q-PCR) using two sets of primers (115 and 247 bp) amplifying different lengths of DNA fragments. The DNA integrity index was calculated as the ratio of q-PCR results of ALU 247/ALU 115bp. Results: Serum DNA integrity was statistically significantly higher in CRC patients compared to the benign and control groups (p<0.001). ROC curves for differentiating CRC patients from normal controls and benign groups had areas under curves of 0.90 and 0.85 respectively. Conclusions: The DNA integrity index is superior to the absolute DNA concentration as a potential serum biomarker for screening and diagnosis of CRC. It may also serve as an indicator for monitoring the progression of CRC patients. Combining CEA and CA19-9 with either of the genetic markers studied is better than either of them alone.

Keywords

References

  1. Agostini M, Pucciarelli M, Vittoria M (2011). Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. Ann Surg Oncol, 18, 2461-8. https://doi.org/10.1245/s10434-011-1638-y
  2. Casadio V, Foca F, Zingaretti C, et al (2013). Gene methylation in rectal cancer: predictive marker of response to chemoradiotherapy. J Cell Physiol, 228, 2343-9. https://doi.org/10.1002/jcp.24405
  3. Chen H, Sun LY, Zheng HQ, et al (2012). Total serum DNA and DNA integrity: diagnostic value in patients with hepatitis B virus-related hepatocellular carcinoma. Pathol, 44, 318-24. https://doi.org/10.1097/PAT.0b013e328353a24c
  4. Cordaux R, Batzer MA (2009). The impact of retrotransposons on human genome evolution. Nature Reviews Genetics, 10, 691-703. https://doi.org/10.1038/nrg2640
  5. da Silva Filho BF, Gurgel AP, Neto MA, et al (2013). Circulating cell-free DNA in serum as a biomarker of colorectal cancer. J Clin Pathol, 66, 775-8. https://doi.org/10.1136/jclinpath-2013-201521
  6. David A, Lieberman D, Douglas K, et al (2012). Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US multi-society task force on colorectal cancer. Gastroentrol, 143, 844-85. https://doi.org/10.1053/j.gastro.2012.06.001
  7. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al (2013). Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 49, 1374-403. https://doi.org/10.1016/j.ejca.2012.12.027
  8. Fong SL, Zhang JT, Lim CK, et al (2009). Comparison of 7 methods for extracting cell-free DNA from serum samples of colorectal cancer patients. Clin Chem, 55, 587-9. https://doi.org/10.1373/clinchem.2008.110122
  9. Gao YJ, He YJ, Yang ZL (2010). Increased integrity of circulating cell free DNA in plasma of patients with acute leukemia. Clin Chem Lab Med, 48, 1651-6.
  10. Hanley R, Christ KM, Canes D (2006). DNA integrity assay: a plasma-based screening tool for the detection of prostate cancer. Clin Cancer Res, 12, 4569-74. https://doi.org/10.1158/1078-0432.CCR-06-0130
  11. Hao TB, Shi W, Shen XJ2, et al (2014). Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. Br J Cancer, 111, 1482-9 https://doi.org/10.1038/bjc.2014.470
  12. Labianca R, Nordlinger B, Beretta.G, et al (2013). Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 24, 64-72
  13. Leszinski G, Lehner J, Gezer U, et al (2013). Increased DNA integrity in colorectal cancer. In Vivo, 3, 299-303.
  14. Luo L, Ting W, Qian H, et al (2014). Changes of TCR repertoire diversity in colorectal cancer after erbitux (cetuximab) in combination with chemotherapy. Am J Cancer Res. 4, 924-33.
  15. Maestranzi S, Przemioslo R, Mitchell H, et al (1998). The effect of benign and malignant liver disease on the tumor markers CA 19-9 and CEA. Ann Clin Biochem, 35, 99-103. https://doi.org/10.1177/000456329803500113
  16. Maio G, Rengucci C, Zoli W, et al (2014). Circulating and stool nucleic acid analysis for colorectal cancer diagnosis. World J Gastroenterol, 20, 957-67. https://doi.org/10.3748/wjg.v20.i4.957
  17. Mead R, Duku M, Bhandari P, et al (2011). Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer, 105, 239-45. https://doi.org/10.1038/bjc.2011.230
  18. Otero E, Chiara L, Rodriguez L, et al (2015). Serum sCD26 for colorectal cancer screening in family-risk individuals: comparison with fecal immunochemical test. British. J Cancer, 112, 375-81. https://doi.org/10.1038/bjc.2014.605
  19. Pinzani P, Salvianti F, Zaccara S (2011). Circulating cell-free DNA in plasma of melanoma patients: qualitative and quantitative considerations. Clin Chim Acta, 412, 2141-5. https://doi.org/10.1016/j.cca.2011.07.027
  20. Umetani N, Kim J, Hiramatsu S, et al (2006). Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clinical Chemistry, 52, 61062-9.
  21. Wang H, Nekrutenko A, Li WH (2000). Densities, length proportions, and other distributional features of repetitive sequences in the human genome estimated from 430 megabases of genomic sequence. Gene, 259, 81-8. https://doi.org/10.1016/S0378-1119(00)00434-0
  22. Wang M, Li Y, Wang Z, et al (2015). The PKA $RI{\alpha}$/A-kinase anchoring proteins 10 signaling pathway and the prognosis of colorectal cancer. J Gastroenterol Hepatol, 30, 496-503. https://doi.org/10.1111/jgh.12689
  23. Zaher MN, Mahpar E, Rafiq S, et al (2014). Clinical features and outcome of sporadic colorectal carcinoma in young patients: a cross-sectional analysis from a Developing Country. ISRN Oncol, 2014, 461570.

Cited by

  1. Circulating Cell-Free DNA in Dogs with Mammary Tumors: Short and Long Fragments and Integrity Index vol.12, pp.1, 2017, https://doi.org/10.1371/journal.pone.0169454
  2. Alteration of the exDNA profile in blood serum of LLC-bearing mice under the decrease of tumour invasion potential by bovine pancreatic DNase I treatment vol.12, pp.2, 2017, https://doi.org/10.1371/journal.pone.0171988
  3. Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer vol.56, pp.1, 2017, https://doi.org/10.1080/0284186X.2016.1253861
  4. Integrity and Quantity of Total Cell-Free DNA in the Diagnosis of Thyroid Cancer: Correlation with Cytological Classification vol.18, pp.7, 2017, https://doi.org/10.3390/ijms18071350
  5. Cell-free DNA as a biomarker in stroke: Current status, problems and perspectives vol.55, pp.1, 2018, https://doi.org/10.1080/10408363.2017.1420032
  6. Clinical significance of peripheral circulating tumor cell counts in colorectal polyps and non-metastatic colorectal cancer vol.16, pp.1, 2018, https://doi.org/10.1186/s12957-017-1305-2
  7. Cell-free nucleic acids are present in blood products and regulate genes of innate immune response vol.58, pp.7, 2018, https://doi.org/10.1111/trf.14613